Is Buying Exactech, Inc. (EXAC) Here a Winning Strategy?

Cornelia Mascio
Ottobre 24, 2017

Other equities research analysts have also recently issued research reports about the company.

Johnson Fistel Investigates Proposed Sale of Exactech, Inc.; Is $42 A Fair Price? Finally, Sidoti cut Exactech from a "buy" rating to a "neutral" rating in a report on Monday. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. They now have a $42.00 price objective on the medical equipment provider's stock.

Exactech, Inc. (NASDAQ:EXAC) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, October 30th. The company had a trading volume of 1,533,092 shares.

The P/E ratio is now 804.81 and the market value is 600.46M. The stock's 50 day moving average price is $31.87 and its 200 day moving average price is $30.09.

Exactech (NASDAQ:EXAC) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.33.

Revenue for the third quarter was expected to be about $61.4 million, impacted in part by Hurricanes Harvey and Irma that caused delays in surgeries and other procedures the required Exactech products. With the purchase of Exactech, the private equity firm plans to "compete with the larger competitors in the orthopedic industry", according to TPG Capital senior adviser Jeff Binder. Next quarter's EPS is forecasted to be $0.39 and the next full year EPS is anticipated to be $1.47. During the same period previous year, the company earned $0.31 EPS.

05/01/2015 - Exactech, Inc. was downgraded to "sell" by analysts at Zacks.

Exactech, Inc. has a 1-year low of $22.20 and a 1-year high of $34.25. "(EXAC) to Neutral" was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of United States and global copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/23/sidoti-downgrades-exactech-inc-exac-to-neutral.html. Certain management shareholders' shares will be exchanged for new equity securities, Exactech said. The shares were sold at an average price of $29.04, for a total value of $29,417.52. The Director now owns $137,272 of the stock per the Form 4 SEC filing. Corporate insiders own 28.30% of the company's stock. Over the past month the firm's stock is 2.40%, 4.58% for the last quarter, 16.58% for the past six-months and 18.26% for the a year ago. Wells Fargo & Company MN now owns 57,447 shares of the medical equipment provider's stock worth $1,448,000 after acquiring an additional 6,590 shares during the period.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE